MX345822B - Separation of triazine derivatives enantiomers using tartaric acid. - Google Patents

Separation of triazine derivatives enantiomers using tartaric acid.

Info

Publication number
MX345822B
MX345822B MX2013006017A MX2013006017A MX345822B MX 345822 B MX345822 B MX 345822B MX 2013006017 A MX2013006017 A MX 2013006017A MX 2013006017 A MX2013006017 A MX 2013006017A MX 345822 B MX345822 B MX 345822B
Authority
MX
Mexico
Prior art keywords
separation
tartaric acid
triazine derivatives
enantiomers
derivatives enantiomers
Prior art date
Application number
MX2013006017A
Other languages
Spanish (es)
Other versions
MX2013006017A (en
Inventor
Cravo Daniel
Helmreich Matthias
Original Assignee
Poxel *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel * filed Critical Poxel *
Publication of MX2013006017A publication Critical patent/MX2013006017A/en
Publication of MX345822B publication Critical patent/MX345822B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention relates to a new process of separation of triazine derivatives enantiomers involving tartaric acid.
MX2013006017A 2010-12-01 2011-11-30 Separation of triazine derivatives enantiomers using tartaric acid. MX345822B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10306327 2010-12-01
PCT/EP2011/071347 WO2012072663A1 (en) 2010-12-01 2011-11-30 Separation of triazine derivatives enantiomers using tartaric acid

Publications (2)

Publication Number Publication Date
MX2013006017A MX2013006017A (en) 2013-07-15
MX345822B true MX345822B (en) 2017-02-17

Family

ID=45047827

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006017A MX345822B (en) 2010-12-01 2011-11-30 Separation of triazine derivatives enantiomers using tartaric acid.

Country Status (24)

Country Link
US (1) US8742103B2 (en)
EP (1) EP2646422B1 (en)
JP (1) JP5758010B2 (en)
KR (1) KR101530924B1 (en)
CN (1) CN103228635B (en)
AU (1) AU2011334992B2 (en)
BR (1) BR112013010115B1 (en)
CA (1) CA2816357C (en)
CY (1) CY1117407T1 (en)
DK (1) DK2646422T3 (en)
EA (1) EA022300B1 (en)
ES (1) ES2548038T3 (en)
HR (1) HRP20151022T1 (en)
HU (1) HUE026090T2 (en)
IL (1) IL226053A (en)
ME (1) ME02208B (en)
MX (1) MX345822B (en)
PL (1) PL2646422T3 (en)
PT (1) PT2646422E (en)
RS (1) RS54397B1 (en)
SI (1) SI2646422T1 (en)
SM (1) SMT201500230B (en)
TW (1) TWI428311B (en)
WO (1) WO2012072663A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019069230A1 (en) 2017-10-02 2019-04-11 Poxel Methods of treating heart failure with preserved ejection fraction
AU2019282727A1 (en) 2018-06-06 2020-11-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
WO2019238647A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804113B1 (en) * 2000-01-26 2004-06-18 Lipha ANIMATED DIHYDRO-1,3,5-TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
FR2853650B1 (en) * 2003-04-10 2006-07-07 Merck Sante Sas AMINE DEDOUBLING PROCESS USEFUL FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH INSULINO-RESISTANCE SYNDROME
US7458318B2 (en) 2006-02-01 2008-12-02 Speedline Technologies, Inc. Off-axis illumination assembly and method
DE102008007314A1 (en) 2008-02-02 2009-08-06 Merck Patent Gmbh Process for the preparation of 3,6-dihydro-1,3,5-triazine derivatives
EA018921B1 (en) 2008-05-23 2013-11-29 Поксел Сас Process for the synthesis of 3,6-dihydro-1,3,5-triazine derivatives

Also Published As

Publication number Publication date
CA2816357C (en) 2015-04-28
RS54397B1 (en) 2016-04-28
EP2646422A1 (en) 2013-10-09
IL226053A0 (en) 2013-06-27
CY1117407T1 (en) 2017-04-26
KR20130093160A (en) 2013-08-21
KR101530924B1 (en) 2015-06-23
CN103228635A (en) 2013-07-31
HUE026090T2 (en) 2016-05-30
EA022300B1 (en) 2015-12-30
US8742103B2 (en) 2014-06-03
AU2011334992A1 (en) 2013-05-30
TW201228999A (en) 2012-07-16
WO2012072663A1 (en) 2012-06-07
EA201300650A1 (en) 2013-11-29
JP5758010B2 (en) 2015-08-05
ME02208B (en) 2016-02-20
BR112013010115B1 (en) 2018-12-04
DK2646422T3 (en) 2015-10-05
ES2548038T3 (en) 2015-10-13
HRP20151022T1 (en) 2015-12-18
PL2646422T3 (en) 2015-12-31
BR112013010115A2 (en) 2016-07-05
CA2816357A1 (en) 2012-06-07
JP2014504281A (en) 2014-02-20
SI2646422T1 (en) 2016-02-29
US20130261300A1 (en) 2013-10-03
IL226053A (en) 2015-03-31
WO2012072663A9 (en) 2012-08-30
SMT201500230B (en) 2015-10-30
AU2011334992B2 (en) 2016-03-24
CN103228635B (en) 2016-03-30
TWI428311B (en) 2014-03-01
MX2013006017A (en) 2013-07-15
EP2646422B1 (en) 2015-07-08
PT2646422E (en) 2015-10-20

Similar Documents

Publication Publication Date Title
HRP20181284T1 (en) Process for production of acrylates from epoxides
MX370649B (en) Process for the preparation of teneligliptin.
UA111142C2 (en) FOR THE PREPARATION OF SUBSTITUTED 2-FLUORACRYLIC ACID DERIVATIVES
EP2563791A4 (en) A process of a quaternary ammonium salt using phosphate
MX2014014138A (en) New process for the preparation of 2-cyclopentyl-6-methoxy-isonic otinic acid.
EP2623580A4 (en) Process for production of beta-sialon
EP2940001A4 (en) Method for producing purified form of amine compound
GEP201706626B (en) Synthesis of (s)-nifuratel
IN2012DN01929A (en)
GB201223271D0 (en) Process for production of an alkylmethacrylate
MX2012010443A (en) Process for the preparation of 5-substituted 1-alkyltetrazoles.
HUE044066T2 (en) Process for the production of methylenediphenyldiisocyanate
MX345822B (en) Separation of triazine derivatives enantiomers using tartaric acid.
IN2014DN09451A (en)
IN2015DN00725A (en)
MX2014009084A (en) Pyrimidooxazocine derivatives as mtor - inhibitors.
MX349985B (en) Process for preparing cis-alkoxy-substituted spirocyclic phenylacetylamino acid esters and cis-alkoxy-substituted spirocyclic 1-h-pyrrolidine-2,4-dione derivatives.
MX2014003936A (en) Method for producing dithiine tetracarboximides.
PL2689069T3 (en) Process for the production of ballast
MX2013002395A (en) Method for producing dithiin-tetracarboximides.
HU1000425D0 (en) Process for the production of montelukast sodium
IN2014DN07498A (en)
MX2014002630A (en) Production of alkaloids without the isolation of intermediates.
PH12014501760A1 (en) Method for stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro[5.5]undecanes
IN2014CN02645A (en)

Legal Events

Date Code Title Description
FG Grant or registration